Cargando…
The PDE4 Inhibitor Tanimilast Blunts Proinflammatory Dendritic Cell Activation by SARS-CoV-2 ssRNAs
Phosphodiesterase 4 (PDE4) inhibitors are immunomodulatory drugs approved to treat diseases associated with chronic inflammatory conditions, such as COPD, psoriasis and atopic dermatitis. Tanimilast (international non-proprietary name of CHF6001) is a novel, potent and selective inhaled PDE4 inhibit...
Autores principales: | Nguyen, Hoang Oanh, Schioppa, Tiziana, Tiberio, Laura, Facchinetti, Fabrizio, Villetti, Gino, Civelli, Maurizio, Del Prete, Annalisa, Sozio, Francesca, Gaudenzi, Carolina, Passari, Mauro, Barbazza, Ilaria, Sozzani, Silvano, Salvi, Valentina, Bosisio, Daniela |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8818995/ https://www.ncbi.nlm.nih.gov/pubmed/35140709 http://dx.doi.org/10.3389/fimmu.2021.797390 |
Ejemplares similares
-
The PDE4 inhibitor tanimilast shows distinct immunomodulatory properties associated with a type 2 endotype and CD141 upregulation
por: Nguyen, Hoang Oanh, et al.
Publicado: (2022) -
The PDE4 Inhibitor Tanimilast Restrains the Tissue-Damaging Properties of Human Neutrophils
por: Schioppa, Tiziana, et al.
Publicado: (2022) -
SARS-CoV-2–associated ssRNAs activate inflammation and immunity via TLR7/8
por: Salvi, Valentina, et al.
Publicado: (2021) -
Tanimilast, A Novel Inhaled Pde4 Inhibitor for the Treatment of Asthma and Chronic Obstructive Pulmonary Disease
por: Facchinetti, Fabrizio, et al.
Publicado: (2021) -
Inhibition of Class I Histone Deacetylase Activity Blocks the Induction of TNFAIP3 Both Directly and Indirectly via the Suppression of Endogenous TNF-α
por: Schioppa, Tiziana, et al.
Publicado: (2022)